CRBP Stock — Corbus Pharmaceuticals Holdings Inc.: Cash, EV, Pipeline

Share price

$7.48

Market cap

$144.7M

Cash

$117.9M

Enterprise value

$26.8M

Balance sheet

Cash	$117.9M
Debt	$0.0M
Net cash	$117.9M
Enterprise value	$26.8M
Basic shares	18.7M shares
Fully diluted shares	23.1M shares
Fully diluted market cap	$173.0M
Cash per share	$6.30

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CRBP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 24, 2026	CRB-913	Phase 1	Obese But Otherwise Healthy Participants	—
Dec 13, 2026 - Jan 24, 2027	CRB-601 monoclonal antibody	Phase 1/2	Solid Tumor	—
Feb 27 - Apr 10	CRB-701	Phase 1/2	Solid Tumor, Adult	—
Jan 12 - Feb 23	CRB-701	Phase 3	Oropharyngeal Carcinoma (OPC)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CRB-701

Phase 1 · Active Modality: antibody drug conjugate (ADC)

Aliases SYS6002

Target Nectin-4

Partnerships Licensed from CSPC Megalith Biopharmaceutical Co. Ltd. (Feb 2023); Corbus holds U.S., Canada, EU/EFTA, U.K., Australia rights. CSPC is investigating CRB-701 in a Phase 3 cervical cancer trial in China.

Indications

Second-line oropharyngeal squamous cell carcinoma (OPSCC) (Phase 1)
Cervical cancer (Phase 1)
Head and neck squamous cell carcinoma (HNSCC) (Phase 1)

Catalysts

— September 2026
— Q1 2027

Status note Next-generation ADC targeting Nectin-4 with MMAE payload. Phase 1/2 Western study (U.S. and Europe) in advanced Nectin-4-expressing solid tumors ongoing; dose expansion ongoing; PD-1 combination arm with Keytruda (pembrolizumab) began dosing Jun 2025. Fast Track: r/r metastatic cervical cancer (Dec 2024); recurrent/metastatic HNSCC previously treated with platinum + anti-PD(L)-1 (Sep 2025). FDA cleared registrational study TEMPO-1 in 2L OPSCC.

CRB-913

Phase 1 · Active Modality: small molecule (oral CB1 inverse agonist)

Target CB1 (cannabinoid receptor type 1)

Partnerships Licensed from Jenrin Discovery, LLC (Sep 2018); exclusive worldwide rights.

Indications

Obesity (Phase 1)

Catalysts

— September 2026

Status note Orally delivered, highly peripherally restricted cannabinoid type-1 (CB1) inverse agonist for obesity. Phase 1a SAD/MAD completed Dec 2025. Phase 1b dose-range finding study CANYON-1 (240 U.S. patients, 4 arms, 12 weeks treatment + 4 weeks follow-up) initiated Dec 2025; last patient completed last clinical visit Aug 2026.

CRB-601

Phase 1 · Terminated Modality: monoclonal antibody

Target αvβ8 integrin

Partnerships Licensed from The Regents of the University of California (May 2021); exclusive license to αvβ8 antibody patents.

Indications

Solid tumors (Phase 1)

Status note Anti-αvβ8 integrin monoclonal antibody that blocks activation of latent TGFβ. Phase 1 dose escalation study completed; program deprioritized — no additional patients will be enrolled.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CRB-701
Lead indication	Oropharyngeal Carcinoma (OPC)
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07768189	Phase 3	Not yet recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Oropharyngeal Carcinoma (OPC)	—
NCT06603844	Phase 1/2	Recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Solid Tumor	—
NCT06265727	Phase 1/2	Recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Solid Tumor, Adult	—
NCT07310901	Phase 1	Active, not recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Obese But Otherwise Healthy Participants	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Corbus Pharmaceuticals Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	1,737,287	no change	0.31%	2026-08-14
ADAR1 Capital Management	421,787	+90,006	0.19%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CRBP — Corbus Pharmaceuticals Holdings Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders